Second untreatable superbug infection found in US

Patient in New York infected with a strain of E. coli highly resistant to last-resort antibiotic treatments


A patient in New York has been infected with a strain of E. coli highly resistant to last-resort antibiotic treatments, according to an article on the Becker's Infection Control and Clinical Quality website.

This is the second U.S. patient with the untreatable superbug infection, following a Pennsylvania patient first made public last month.

The mcr-1 gene gives bacteria resistance to colistin, a last-line-of-defense antibiotic used to combat a number of resistant microorganisms.

Going into 2017, the White House has requested $1.1 billion be allocated to efforts to combat antibiotic resistance in the U.S. 

Read the article.

 

 



July 6, 2016


Topic Area: Infection Control


Recent Posts

Waco Family Medicine Achieves Savings and Bold Design with Wood Selections

Case study: The healthcare facility incorporated over 25,000 square feet of wood and saved over $400,000.


Alleged Ransomware Administrator Extradited from South Korea

The Phobos ransomware has been used globally to target over 1,000 organizations, including healthcare.


Design Plans Unveiled for New Intermountain St. Vincent Regional Hospital

The new hospital will be a 14-floor, 737,000 square-foot facility in Billings, Montana.


Ground Broken on New Pediatric Health Campus in Dallas

The new campus will replace the existing Children’s Medical Center Dallas.


Pre-Construction Strategies for Successful Facilities Projects

Savvy decisions can help facilities meet long-term goals by creating consistency and eliminating waste.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.